microRNA在喉鳞状细胞癌中的研究进展

卜倩倩; 高伟; 吴勇延; 郭培钰; 王斌全

doi:10.13201/j.issn.2096-7993.2021.10.019

microRNA在喉鳞状细胞癌中的研究进展

- 山西医科大学第一医院耳鼻咽喉头颈外科耳鼻咽喉头颈肿瘤山西省重点实验室(太原，030001)

详细信息

通讯作者: 王斌全, E-mail: wbq_xy@sxent.org

中图分类号: R739.65

收稿日期: 2020-12-29

刊出日期: 2021-10-05

Research progress of microRNA in laryngeal squamous cell carcinoma

More Information

Corresponding author: WANG Binquan, E-mail: wbq_xy@sxent.org

Received Date: 29 December 2020

Publish Date: 05 October 2021

摘要

- 喉肿瘤 /
- 癌, 鳞状细胞 /
- microRNA
Abstract: Laryngeal carcinoma is one of the most common malignant tumors in the area of head and neck, and the main pathological type is laryngeal squamous cell carcinoma. Due to the fact that the disease usually have no overt clinical symptoms at the early stage and easy to relapse, it has a poor prognosis and low five-year survival rate. microRNA is a class of endogenous, non-coding RNA with a length of 19-25 nucleotides. microRNAs, mainly regulate the expression of target genes at the post-transcriptional level after complementing and pairing with the 3'-UTR area of the target gene. Studies have shown that the abnormal expression of microRNA is closely related to the occurrence, development, metastasis and prognosis of various cancers including laryngeal carcinoma. In this article, the research progress of microRNA in laryngeal squamous cell carcinoma is reviewed.
- laryngeal neoplasms /
- carcinoma, squamous cell /
- microRNA

HTML全文

参考文献(44)

[1]	胡晨, 薛继尧, 龚洪立, 等. 喉鳞状细胞癌局部复发影响因素及预后分析[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(9): 773-776. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH202009002.htm
[2]	Li Y, Liu J, Hu W, et al. miR-424-5p Promotes Proliferation, Migration and Invasion of Laryngeal Squamous Cell Carcinoma[J]. Onco Targets Ther, 2019, 12: 10441-10453. doi: 10.2147/OTT.S224325
[3]	Lapa R, Barros-Filho MC, Marchi FA, et al. Integrated miRNA and mRNA expression analysis uncovers drug targets in laryngeal squamous cell carcinoma patients[J]. Oral Oncol, 2019, 93: 76-84. doi: 10.1016/j.oraloncology.2019.04.018
[4]	Luo M, Sun G, Sun JW. MiR-196b affects the progression and prognosis of human LSCC through targeting PCDH-17[J]. Auris Nasus Larynx, 2019, 46(4): 583-592. doi: 10.1016/j.anl.2018.10.020
[5]	Liu C, Yu Z, Huang S, et al. Combined identification of three miRNAs in serum as effective diagnostic biomarkers for HNSCC[J]. EBioMedicine, 2019, 50: 135-143. doi: 10.1016/j.ebiom.2019.11.016
[6]	张卓远, 付汉江, 吕星, 等. miRNA功能研究进展[J]. 军事医学科学院院刊, 2005, 29(6): 571-575. doi: 10.3969/j.issn.1674-9960.2005.06.021
[7]	王苹, 付涛, 王绪锐, 等. 应用微阵列芯片分析喉鳞状细胞癌miRNA与正常黏膜表达差异的初步研究[J]. 临床耳鼻咽喉头颈外科杂志, 2010, 24(12): 535-538. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201012006.htm
[8]	Cheng Y, Zhu H, Gao W. MicroRNA-330-3p represses the proliferation and invasion of laryngeal squamous cell carcinoma through downregulation of Tra2β-mediated Akt signaling[J]. Mol Cell Probes, 2020, 52: 101574. doi: 10.1016/j.mcp.2020.101574
[9]	卡衣赛尔·卡哈尔, 阿布拉江·托合提, 唐亮, 等. miR-340-5p对喉癌Hep2细胞增殖的影响及其内在分子机制研究[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(2): 140-145. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH202002010.htm
[10]	Wang C, Huang Y, Zhang J, et al. MiRNA-339-5p suppresses the malignant development of gastric cancer via targeting ALKBH1[J]. Exp Mol Pathol, 2020, 115: 104449. doi: 10.1016/j.yexmp.2020.104449
[11]	Hou G, Xu W, Jin Y, et al. MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D[J]. Biochem Biophys Res Commun, 2019, 519(4): 747-753. doi: 10.1016/j.bbrc.2019.09.029
[12]	Wang S, Wang Z, Wang Q, et al. Clinical significance of the expression of miRNA-21, miRNA-31 and miRNA-let7 in patients with lung cancer[J]. Saudi J Biol Sci, 2019, 26(4): 777-781. doi: 10.1016/j.sjbs.2018.12.009
[13]	Wang D, Wang X, Si M, et al. Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages[J]. Cancer Lett, 2020, 474: 36-52. doi: 10.1016/j.canlet.2020.01.005
[14]	Yan Z, Xiao Y, Chen Y, et al. Screening and identification of epithelial-to-mesenchymal transition-related circRNA and miRNA in prostate cancer[J]. Pathol Res Pract, 2020, 216(2): 152784. doi: 10.1016/j.prp.2019.152784
[15]	Chen F, Zhou H, Wu C, et al. Identification of miRNA profiling in prediction of tumor recurrence and progress and bioinformatics analysis for patients with primary esophageal cancer: Study based on TCGA database[J]. Pathol Res Pract, 2018, 214(12): 2081-2086. doi: 10.1016/j.prp.2018.10.009
[16]	Xu X, Liu T, Wang Y, et al. miRNA-mRNA Associated With Survival in Endometrial Cancer[J]. Front Genet, 2019, 10: 743. doi: 10.3389/fgene.2019.00743
[17]	Wang Y, Huang Q, Li F. miR-140-5p targeted FGF9 and inhibited the cell growth of laryngeal squamous cell carcinoma[J]. Biochem Cell Biol, 2020, 98(2): 83-89. doi: 10.1139/bcb-2018-0351
[18]	Ye D, Zhou C, Deng H, et al. MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting the PI3K/Akt signaling pathway[J]. Cancer Manag Res, 2019, 11: 3801-3812. doi: 10.2147/CMAR.S199291
[19]	Li X, Wang HL, Peng X, et al. miR-1297 mediates PTEN expression and contributes to cell progression in LSCC[J]. Biochem Biophys Res Commun, 2012, 427(2): 254-260. doi: 10.1016/j.bbrc.2012.09.025
[20]	Wu D, Zhang X, Liu Z, et al. Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma[J]. Biochem Biophys Res Commun, 2018, 503(3): 1378-1384. doi: 10.1016/j.bbrc.2018.07.051
[21]	Zhang F, Cao H. MicroRNA1433p suppresses cell growth and invasion in laryngeal squamous cell carcinoma via targeting the kRas/Raf/MEK/ERK signaling pathway[J]. Int J Oncol, 2019, 54(2): 689-701.
[22]	Chen X, Zhang L, Tang S. MicroRNA-4497 functions as a tumor suppressor in laryngeal squamous cell carcinoma via negatively modulation the GBX2[J]. Auris Nasus Larynx, 2019, 46(1): 106-113. doi: 10.1016/j.anl.2018.05.005
[23]	Wang J, Zhou Y, Lu J, et al. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma[J]. Med Oncol, 2014, 31(9): 148. doi: 10.1007/s12032-014-0148-8
[24]	徐志远, 秦永. 喉鳞状细胞癌患者血清中miRNAs表达谱分析[J]. 医学综述, 2019, 25(23): 4771-4775. doi: 10.3969/j.issn.1006-2084.2019.23.034
[25]	Erkul E, Yilmaz I, Gungor A, et al. MicroRNA-21 in laryngeal squamous cell carcinoma: Diagnostic and prognostic features[J]. Laryngoscope, 2017, 127(2): E62-E66. doi: 10.1002/lary.26226
[26]	Wu Y, Yu J, Ma Y, et al. miR-148a and miR-375 may serve as predictive biomarkers for early diagnosis of laryngeal carcinoma[J]. Oncol Lett, 2016, 12(2): 871-878. doi: 10.3892/ol.2016.4707
[27]	Lapa R, Barros-Filho MC, Marchi FA, et al. Integrated miRNA and mRNA expression analysis uncovers drug targets in laryngeal squamous cell carcinoma patients[J]. Oral Oncol, 2019, 93: 76-84. doi: 10.1016/j.oraloncology.2019.04.018
[28]	Giovannetti E, Erozenci A, Smit J, et al. Molecular mechanisms underlying the role of microRNAs(miRNAs)in anticancer drug resistance and implications for clinical practice[J]. Crit Rev Oncol Hematol, 2012, 81(2): 103-122. doi: 10.1016/j.critrevonc.2011.03.010
[29]	何丹, 王苹, 李亚纯, 等. MiRNA210通过NUPR1基因靶向调控喉癌多药耐药性的研究[J]. 中国实验诊断学, 2019, 23(3): 511-515. doi: 10.3969/j.issn.1007-4287.2019.03.053
[30]	Lin XJ, Liu H, Li P, et al. miR-936 Suppresses Cell Proliferation, Invasion, and Drug Resistance of Laryngeal Squamous Cell Carcinoma and Targets GPR78[J]. Front Oncol, 2020, 10: 60. doi: 10.3389/fonc.2020.00060
[31]	Li R, Chen S, Zhan J, et al. Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell carcinoma via STAT3 activation[J]. Cell Death Dis, 2020, 11(1): 41. doi: 10.1038/s41419-020-2232-7
[32]	Liu J, Tang Q, Li S, et al. Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells[J]. Oncotarget, 2016, 7(52): 86446-86456. doi: 10.18632/oncotarget.13424
[33]	张春明, 高伟, 吴勇延, 等. 长链非编码RNA LINC00261在喉鳞状细胞癌中的表达及意义[J]. 临床耳鼻咽喉头颈外科杂志, 2017, 31(1): 68-71. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201802003.htm
[34]	Fang R, Huang Y, Xie J, et al. Downregulation of miR-29c-3p is associated with a poor prognosis in patients with laryngeal squamous cell carcinoma[J]. Diagn Pathol, 2019, 14(1): 109. doi: 10.1186/s13000-019-0893-2
[35]	Gao W, Zhang C, Li W, et al. Promoter Methylation-Regulated miR-145-5p Inhibits Laryngeal Squamous Cell Carcinoma Progression by Targeting FSCN1[J]. Mol Ther, 2019, 27(2): 365-379. doi: 10.1016/j.ymthe.2018.09.018
[36]	Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res, 2008, 18(10): 997-1006. doi: 10.1038/cr.2008.282
[37]	Hui L, Zhang J, Guo X. MiR-125b-5p suppressed the glycolysis of laryngeal squamous cell carcinoma by down-regulating hexokinase-2[J]. Biomed Pharmacother, 2018, 103: 1194-1201. doi: 10.1016/j.biopha.2018.04.098
[38]	Xu Y, Lin YP, Yang D, et al. Expression of serum microRNA-378 and its clinical significance in laryngeal squamous cell carcinoma[J]. Eur Rev Med Pharmacol Sci, 2016, 20(24): 5137-5142.
[39]	Kalluri R. The biology and function of exosomes in cancer[J]. J Clin Invest, 2016, 126(4): 1208-1215. doi: 10.1172/JCI81135
[40]	Huang W, Yan Y, Liu Y, et al. Exosomes with low miR-34c-3p expression promote invasion and migration of non-small cell lung cancer by upregulating integrin α2β1[J]. Signal Transduct Target Ther, 2020, 5(1): 39. doi: 10.1038/s41392-020-0133-y
[41]	Zhao Q, Zheng X, Guo H, et al. Serum Exosomal miR-941 as a promising Oncogenic Biomarker for Laryngeal Squamous Cell Carcinoma[J]. J Cancer, 2020, 11(18): 5329-5344. doi: 10.7150/jca.45394
[42]	Ariston Gabriel AN, Wang F, Jiao Q, et al. The involvement of exosomes in the diagnosis and treatment of pancreatic cancer[J]. Mol Cancer, 2020, 19(1): 132. doi: 10.1186/s12943-020-01245-y
[43]	Fang T, Lv H, Lv G, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer[J]. Nat Commun, 2018, 9(1): 191. doi: 10.1038/s41467-017-02583-0
[44]	He L, Ping F, Fan Z, et al. Salivary exosomal miR-24-3p serves as a potential detective biomarker for oral squamous cell carcinoma screening[J]. Biomed Pharmacother, 2020, 121: 109553. doi: 10.1016/j.biopha.2019.109553